Last reviewed · How we verify

Lithium (LI)

Weill Medical College of Cornell University · FDA-approved active Small molecule

Lithium modulates intracellular signaling pathways, particularly inhibiting inositol monophosphatase and glycogen synthase kinase-3 (GSK-3), which alters neurotransmitter activity and neuroprotective processes in the brain.

Lithium modulates intracellular signaling pathways, particularly inhibiting inositol monophosphatase and glycogen synthase kinase-3 (GSK-3), which alters neurotransmitter activity and neuroprotective processes in the brain. Used for Bipolar I disorder (acute mania and maintenance), Major depressive disorder (augmentation therapy), Bipolar depression.

At a glance

Generic nameLithium (LI)
Also known asDepakote
SponsorWeill Medical College of Cornell University
Drug classMood stabilizer
TargetInositol monophosphatase, GSK-3 (glycogen synthase kinase-3)
ModalitySmall molecule
Therapeutic areaPsychiatry
PhaseFDA-approved

Mechanism of action

Lithium's exact mechanism remains incompletely understood, but it is known to inhibit GSK-3 and affect phosphatidylinositol signaling, leading to changes in gene expression and neuroplasticity. These effects result in mood stabilization and neuroprotection, making it effective in bipolar disorder and depression. The drug also influences serotonin and norepinephrine systems, contributing to its therapeutic effects.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: